Prostatic carcinoma metastatic to bone: Sensitivity and specificity of prostate-specific antigen and prostatic acid phosphatase in decalcified material

1985 ◽  
Vol 29 (4) ◽  
pp. 265-268 ◽  
Author(s):  
Niranjan T. Shah ◽  
Steven E. Tuttle ◽  
Stephan L. Storbel ◽  
Leena Gandhi
Keyword(s):  
Acid Phosphatase ◽  
Prostate Specific Antigen ◽  
Sensitivity And Specificity ◽  
Prostatic Carcinoma ◽  
Specific Antigen ◽  
Prostatic Acid Phosphatase

Diagnostic Utility of P504S/p63 Cocktail, Prostate-Specific Antigen, and Prostatic Acid Phosphatase in Verifying Prostatic Carcinoma Involvement in Seminal Vesicles: A Study of 57 Cases of Radical Prostatectomy Specimens of Pathologic Stage pT3b

2010 ◽  
Vol 134 (7) ◽  
pp. 983-988 ◽  
Author(s):  
Aaron M. Harvey ◽  
Beverly Grice ◽  
Candice Hamilton ◽  
Luan D. Truong ◽  
Jae Y. Ro ◽  
...  
Keyword(s):  
Acid Phosphatase ◽  
Radical Prostatectomy ◽  
Seminal Vesicle ◽  
Prostate Specific Antigen ◽  
Prostatic Carcinoma ◽  
Specific Antigen ◽  
Prostatic Acid Phosphatase ◽  
Growth Patterns ◽  
Nuclear Staining ◽  
Pathologic Stage

Abstract Context.—Seminal vesicle invasion by prostatic carcinoma is directly associated with tumor staging; verification is challenging when the tumor demonstrates cribriform or papillary growth patterns or there are back-to-back small-gland proliferations. P504S is overexpressed in prostatic carcinoma and high-grade prostatic intraepithelial neoplasia with cytoplasmic immunoreactivity. p63 has positive immunoreactivity in basal cell nuclei of benign prostatic glands. Many researchers use a combination of these antibodies and their different colors. Objective.—To evaluate the usefulness of a single-color P504S/p63 cocktail immunostain in verifying prostatic carcinoma within the seminal vesicle. Design.—Sections from 57 radical prostatectomy specimens of pathologic stage pT3b that contain seminal vesicle with prostatic carcinoma involvement were immunostained with primary antibodies against prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP) and a cocktail of antibodies against P504S and p63. Results.—Prostatic carcinoma cells from all 57 cases were diffusely positive for P504S, PSA, and PAP with cytoplasmic staining and no p63 nuclear staining. Seminal vesicle epithelium from all 57 cases was negative for all 3 markers with distinct p63 nuclear staining of the basal cells. Benign prostatic tissue was positive for PSA and PAP, as well as for p63, but negative for P504S. Conclusions.—The P504S/p63 one-color cocktail is a practical and cost-effective stain to differentiate prostatic carcinoma that involves the seminal vesicle from seminal vesicle epithelium. It is superior to PSA or PAP when sections contain both seminal vesicle and benign glands because PSA and PAP cannot distinguish benign from malignant glands.

Evaluation of a monoclonal immunoradiometric assay for prostate-specific antigen.

1987 ◽  
Vol 33 (12) ◽  
pp. 2257-2261 ◽  
Author(s):  
R C Rock ◽  
D W Chan ◽  
D Bruzek ◽  
C Waldron ◽  
J Oesterling ◽  
...  
Keyword(s):  
Enzyme Activity ◽  
Acid Phosphatase ◽  
Prostate Specific Antigen ◽  
Prostatic Carcinoma ◽  
Mass Measurement ◽  
Clinical Stage ◽  
Specific Antigen ◽  
Prostatic Acid Phosphatase ◽  
Immunoradiometric Assay ◽  
Enzyme Activity Assay

Abstract We evaluated the analytical performance of a new monoclonal immunoradiometric assay ("M-PSA") for prostate-specific antigen ("Tandem"; Hybritech Inc.) in comparison with a monoclonal immunoradiometric assay ("M-PAP") for mass measurement of prostatic acid phosphatase ("Tandem") and with a conventional enzyme-activity assay ("E-PAP") for prostatic acid phosphatase (EC 3.1.3.2). For M-PSA, the CVs were 1.3-3.0% within-run and 3.0-4.9% between-run. The minimum detectable mass concentration was 0.10 microgram/L, and linearity extended to 100 micrograms/L. The reference interval for M-PSA in 178 healthy men was 0-2.8 micrograms/L. Serum specimens from men with prostatic disease (primarily prostatic carcinoma and benign prostatic hypertrophy) were assayed by the three methods. Correlation was best between mass measurement (M-PAP) and enzyme activity (E-PAP) for prostatic acid phosphatase (r = 0.958). Results for PSA did not correlate well with those for either M-PAP (r = 0.629) or E-PAP (r = 0.387). PSA was increased in a higher percentage of specimens from men with earlier (clinical stage B) prostatic carcinoma than were results from either assay for PAP.

Prostate Specific Antigen and Prostatic Acid Phosphatase Immunoreactivity as Prognostic Indicators of Advanced Prostatic Carcinoma

1993 ◽  
Vol 149 (5 Part 1) ◽  
pp. 1020-1023 ◽  
Author(s):  
Hideki Sakai ◽  
Yasuo Yogi ◽  
Yuzo Minami ◽  
Yoshiaki Yushita ◽  
Hiroshi Kanetake ◽  
...  
Keyword(s):  
Acid Phosphatase ◽  
Prostate Specific Antigen ◽  
Prostatic Carcinoma ◽  
Specific Antigen ◽  
Prostatic Acid Phosphatase ◽  
Prognostic Indicators ◽  
Advanced Prostatic Carcinoma

Serum Prostate-Specific Antigen Determination in Prostatic Carcinoma

1987 ◽  
Vol 2 (3) ◽  
pp. 184-186 ◽  
Author(s):  
Alessandro Tizzani ◽  
Giovanni Casetta ◽  
Paolo Piana ◽  
Maurizio Bellina ◽  
Ferdinando Pecchio ◽  
...  
Keyword(s):  
Acid Phosphatase ◽  
Prostate Specific Antigen ◽  
Prostatic Cancer ◽  
Prostatic Carcinoma ◽  
Specific Antigen ◽  
Prostatic Acid Phosphatase ◽  
Prostatic Hyperplasia ◽  
Number Of Patients ◽  
Antigen Determination ◽  
Early Predictor

Prostate-specific antigen (PSA) is a tissue-specific glycoprotein identified by Wang in 1979. It is synthesized in the prostate independently of prostatic acid phosphatase (PAP). A total of 199 subjects were divided into four groups: controls aged less than 50 years, controls aged more than 50 years, patients with benign prostatic hyperplasia (BPH) and patients with prostatic carcinoma. PSA cut-off value was set at 10 ng/ml (mean for the BPH group plus 2 SD). With this cut-off value PSA could not be used as an early predictor of prostatic carcinoma. The association of PSA and PAP in prostatic cancer increases the number of patients with positive biological markers.

Clinical Usefulness of Prostate-Specific Antigen and Prostatic Acid Phosphatase in Patients with Prostatic Cancer

Tumor Biology ◽  
1990 ◽  
Vol 11 (6) ◽  
pp. 289-294 ◽  
Author(s):  
X. Filella ◽  
R. Molina ◽  
J. Jo ◽  
B. Umbert ◽  
J.L. Bedini ◽  
...  
Keyword(s):  
Acid Phosphatase ◽  
Prostate Specific Antigen ◽  
Prostatic Cancer ◽  
Specific Antigen ◽  
Prostatic Acid Phosphatase ◽  
Clinical Usefulness
Sign in / Sign up

Export Citation Format

Share Document